Boormans JL - Search Results

1

The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial.

Rutten VC, Salhi Y, Robbrecht GJ, de Wit R, van Leenders GJLH, Zuiverloon TCM, Boormans JL. Rutten VC, et al. Among authors: boormans jl. BMC Cancer. 2023 Jun 13;23(1):539. doi: 10.1186/s12885-023-10963-7. BMC Cancer. 2023. PMID: 37312054 Free PMC article. Clinical Trial.

2

Reply by Authors.

van Kessel KEM, de Jong JJ, Ziel-van der Made ACJ, Roshani H, Haensel SM, Wolterbeek JH, Boevé ER, Oomens EHGM, van Casteren NJ, Krispin M, Boormans JL, Steyerberg EW, van Criekinge W, Zwarthoff EC. van Kessel KEM, et al. Among authors: boormans jl. J Urol. 2020 Nov;204(5):1063. doi: 10.1097/JU.0000000000001236. Epub 2020 Jul 6. J Urol. 2020. PMID: 32628101 No abstract available.

3

Confirmation of the association of TMPRSS2(exon 0):ERG expression and a favorable prognosis of primary prostate cancer.

Boormans JL, Porkka K, Visakorpi T, Trapman J. Boormans JL, et al. Eur Urol. 2011 Jul;60(1):183-4. doi: 10.1016/j.eururo.2011.03.028. Epub 2011 Mar 29. Eur Urol. 2011. PMID: 21474234 No abstract available.

4

Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.

Boormans JL, Wildhagen MF, Bangma CH, Verhagen PC, van Leenders GJ. Boormans JL, et al. BJU Int. 2008 Dec;102(11):1589-93. doi: 10.1111/j.1464-410X.2008.07904.x. Epub 2008 Aug 14. BJU Int. 2008. PMID: 18710447

5

An activating mutation in AKT1 in human prostate cancer.

Boormans JL, Hermans KG, van Leenders GJ, Trapman J, Verhagen PC. Boormans JL, et al. Int J Cancer. 2008 Dec 1;123(11):2725-6. doi: 10.1002/ijc.23787. Int J Cancer. 2008. PMID: 18798258 No abstract available.

6

E17K substitution in AKT1 in prostate cancer.

Boormans JL, Korsten H, Ziel-van der Made AC, van Leenders GJ, Verhagen PC, Trapman J. Boormans JL, et al. Br J Cancer. 2010 May 11;102(10):1491-4. doi: 10.1038/sj.bjc.6605673. Epub 2010 Apr 20. Br J Cancer. 2010. PMID: 20407443 Free PMC article.

7

No evidence of FGFR3 mutations in prostate cancer.

Zuiverloon TC, Boormans JL, Trapman J, van Leenders GJ, Zwarthoff EC. Zuiverloon TC, et al. Among authors: boormans jl. Prostate. 2011 May;71(6):637-41. doi: 10.1002/pros.21279. Epub 2010 Oct 18. Prostate. 2011. PMID: 20957671

8

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B, Trapman J. van Leenders GJ, et al. Among authors: boormans jl. Mod Pathol. 2011 Aug;24(8):1128-38. doi: 10.1038/modpathol.2011.65. Epub 2011 Apr 15. Mod Pathol. 2011. PMID: 21499236 Free article.

9

Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?

Beukers W, Meijer T, Vissers CJ, Boormans JL, Zwarthoff EC, van Leenders GJ. Beukers W, et al. Among authors: boormans jl. Virchows Arch. 2012 Aug;461(2):149-56. doi: 10.1007/s00428-012-1277-0. Epub 2012 Jul 10. Virchows Arch. 2012. PMID: 22777576 Free PMC article.

10

Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.

Boormans JL, Korsten H, Ziel-van der Made AJ, van Leenders GJ, de Vos CV, Jenster G, Trapman J. Boormans JL, et al. Int J Cancer. 2013 Jul 15;133(2):335-45. doi: 10.1002/ijc.28025. Epub 2013 Feb 12. Int J Cancer. 2013. PMID: 23319146

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters